CANCER ZERO
Live / Applied — Fourth extension granted (statement of use) (as of 09 Mar 2026)
What this means for you
Not registered yet, but its 05 Dec 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97703809
- Mark type
- Stylized text
- Filed
- 05 Dec 2022
- Published for opposition
- 16 Jan 2024
- Attorney of record
- Mark A. Jansen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, oncological preparations; reagent, diagnostic and therapeutic preparations for medical use in oncology; targeted medical preparations for use in oncology; pharmaceutical preparations for use in the treatment of cancer and tumors; pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; pharmaceutical and biological preparations for use in immunotherapies to improve immune system function; pharmaceutical and biological preparations combining immunotherapies and chemotherapies for treatments in the field of oncology; medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of immunological and oncological diseases and disorders; pharmaceutical and biological preparations comprised of modified t cells used for multiple modes of treatment against tumor resistance and immunosuppression; pharmaceuticals in the nature of cell therapeutics for the treatment and prevention of cancer; engineered cell therapies, namely, engineered T cells, immune cells, and antibodies for the treatment and prevention of cancer
- Class 042 — Scientific and technological services: Research, development, and evaluation of new products; pharmaceutical, medicine, and vaccine research and development services; technical research in the field of pharmaceutical studies; laboratory analysis and research into new drugs and pharmaceutical products; development of scientific measuring and testing methods in the field of oncology; design, development, research, and conducting clinical trials for others in connection with drugs, pharmaceuticals, and cellular therapies for the treatment and/or prevention of cancer; research and development services in the fields of oncology, immunotherapy, chemotherapy and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology; research and development in the field of bioengineering and genetic engineering; Research and development of treatments and therapies in the field of oncology; Research and development of pharmaceuticals for the treatment and prevention of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Scientific research for medical purposes in the field of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Molecular, cellular, and genetic research and development; Development of processes and methods for the manufacturing and engineering of cells and molecules; development of therapeutics and treatments for the prevention of cancer, autoimmune, inflammatory, genetic and infectious diseases and disorders; Development of diagnostic medical measuring and testing methods in the field of cancer therapy and treatment
- Class 044 — Medical, beauty and agricultural services: Medical services; Providing health information; Providing health information in the field of bioengineering and genetic engineering; Providing health information in the field of autoimmune, inflammatory and infectious diseases and disorders, cancer prevention and treatment; Medical diagnosis and treatment of cancer, autoimmune, inflammatory, and infectious diseases and disorders
Owner
- IN8bio, Inc., New York, NY, US
- IN8bio, Inc., New York, NY, US
Prosecution history
- 10 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Mar 2026 — SOU EXTENSION 4 GRANTED
- 09 Mar 2026 — SOU EXTENSION 4 FILED
- 09 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 16 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Jul 2025 — SOU EXTENSION 3 GRANTED
- 15 Jul 2025 — SOU EXTENSION 3 FILED
- 15 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Mar 2025 — SOU EXTENSION 2 GRANTED
- 11 Mar 2025 — SOU EXTENSION 2 FILED
- 11 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 09 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Sept 2024 — SOU EXTENSION 1 GRANTED
- 09 Sept 2024 — SOU EXTENSION 1 FILED